BioSig Technologies, Inc. Added to Membership of Russell 3000® Index
July 01 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device
company developing a proprietary biomedical signal processing
platform designed to address an unmet technology need for the
electrophysiology (EP) marketplace, today announced that it has
been added as a member of the broad-market Russell
3000® Index, effective after the US market opens on July 1, as
part of the 2019 Russell US Indexes reconstitution.
Annual reconstitution of the Russell US Indexes captures the
4,000 largest US stocks as of May 10, ranking them by total market
capitalization. Membership in the Russell 3000® Index, which
remains in place for one year, means automatic inclusion in the
large-cap Russell 1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell US
Indexes primarily by objective, market-capitalization rankings and
style attributes.
“We are proud to join the Russell 3000® family. This
membership marks an important milestone in the development of our
Company, helping us with our mission to drive innovation in the
biomedical signal processing space and address unmet clinical
needs,” commented Kenneth L. Londoner, Chairman and CEO of BioSig
Technologies, Inc. “Reaching new investment audiences is critically
important to emerging growth companies, and we look forward to this
new chapter, as we scale up our clinical and manufacturing
activities ahead of commercialization."
The Russell US Indexes are widely used by investment managers
and institutional investors for passive funds and investment
products and as benchmarks for active investment strategies.
Approximately $9 trillion in assets are benchmarked against Russell
US Indexes. Russell US Indexes are part of FTSE Russell’s suite of
index offerings.
For more information on the Russell 3000® Index and the
Russell US Indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About FTSE RussellFTSE Russell is a global
index leader that provides innovative benchmarking, analytics and
data solutions for investors worldwide. FTSE Russell calculates
thousands of indexes that measure and benchmark markets and asset
classes in more than 70 countries, covering 98% of the investable
market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $16
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create ETFs, structured products
and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
its offering. FTSE Russell is wholly owned by London Stock Exchange
Group. For more information, visit www.ftserussell.com
About BioSig Technologies BioSig Technologies
is a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EP™ System. The
technology has been developed to address an unmet need in a large
and growing market.
The Company’s first product, PURE EP™ System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory.
The system is indicated for use under the supervision of licensed
healthcare practitioners who are responsible for interpreting the
data. This novel cardiac signal acquisition and display system is
engineered to assist electrophysiologists in clinical
decision-making during electrophysiology procedures in patients
with abnormal heart rates and rhythms. BioSig’s ultimate goal is to
deliver technology to improve upon catheter ablation treatments for
the prevalent and potentially deadly arrhythmias, Atrial
Fibrillation and Ventricular Tachycardia. BioSig has partnered with
Minnetronix on technology development and received FDA 510(k)
clearance for the PURE EP™ System in August 2018.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
12424 Wilshire Blvd, Ste 745
Los Angeles, CA 90025
ndrapeau@biosigtech.com
310-620-9320
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024